ARKETIS Tablet Ref.[51107] Active ingredients: Paroxetine

Source: Medicines Authority (MT)  Revision Year: 2021  Publisher: Medochemie Ltd, 1-10 Constantinoupoleos street, 3011 Limassol, Cyprus

Product name and form

Arketis 10 mg, tablets.

Arketis 20 mg, tablets.

Arketis 30 mg, tablets.

Arketis 40 mg, tablets.

Pharmaceutical Form

Tablet.

10 mg: biconvex off white round tablet inscribed 10 on one side.

20 mg: flat faced bevel edged off white round tablet inscribed 20 on one side with a score line. The tablet can be divided into equal doses.

30 mg: flat faced bevel edged off white round tablet with a score line. The tablet can be divided into equal doses.

40 mg: capsule shaped off white tablet with a score line. The tablet can be divided into equal doses.

Qualitative and quantitative composition

Arketis 10 mg: Each tablet contains 10 mg paroxetine (as paroxetine hydrochloride anhydrate).

Arketis 20 mg: Each tablet contains 20 mg paroxetine (as paroxetine hydrochloride anhydrate).

Arketis 30 mg: Each tablet contains 30 mg paroxetine (as paroxetine hydrochloride anhydrate).

Arketis 40 mg: Each tablet contains 40 mg paroxetine (as paroxetine hydrochloride anhydrate.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Paroxetine

Paroxetine is a potent and selective inhibitor of 5-hydroxytryptamine (5-HT, serotonin) uptake and its antidepressant action and effectiveness in the treatment of OCD, Social Anxiety disorder/Social Phobia, General Anxiety Disorder, Post-Traumatic Stress Disorder and Panic Disorder is thought to be related to its specific inhibition of 5-HT uptake in brain neurones.

List of Excipients

Cellulose microcrystalline (E460)
Calcium hydrogen phosphate dihydrate (E341)
Croscarmellose sodium (E468)
Silica colloidal anhydrous (E551)
Magnesium stearate (E470b)

Pack sizes and marketing

Polyvinylchloride foil – aluminium foil blisters: packs containing 10, 14, 20, 28, 30, 50, 56, 60, 90, 98, 100, 120, 180, or 500 tablets are available.

Not all pack sizes may be marketed.

Marketing authorization holder

Medochemie Ltd, 1-10 Constantinoupoleos street, 3011 Limassol, Cyprus

Marketing authorization dates and numbers

MA032/06601
MA032/06602
MA032/06603
MA032/06604

Date of first authorisation: 4th January 2008
Date of latest renewal: 19th January 2012

Drugs

Drug Countries
ARKETIS Cyprus, Estonia, Lithuania, Malta, Poland, Romania

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.